INSERM UMR_S 999
Director : Professor Marc HUMBERT
|
Hopital Bicêtre |
Hopital Bicêtre |
Hôpital Marie Lannelongue |
| Faculté de Médecine Paris-Saclay | Service de Pneumologie et Réanimation Respiratoire | Groupe Hospitalier Paris Saint Joseph |
| Bâtiment de recherche (Porte 16) |
Centre National de Référence de l'Hypertension Pulmonaire | Département de recherche médicale |
| 63 rue Gabriel Péri | 78 Rue du Général Leclerc |
133, Avenue de la Résistance |
| 94276 Le Kremlin-Bicêtre, France | 94276 Le Kremlin-Bicêtre, France |
92350 Le Plessis-Robinson, France |
Aims:
Pulmonary hypertension describes a group of devastating diseases, comprising idiopathic and associated forms, causing breathlessness, loss of exercise capacity and death due to elevated pulmonary artery pressure and subsequent right heart failure. Pulmonary arterial hypertension is defined by a chronic elevation in mean pulmonary arterial pressure (mPAP) > 20mmHg at rest, with a normal pulmonary artery wedge pressure (≤ 15 mmHg) and increased PVR > 2 Wood Units. Extensive pulmonary artery remodeling with loss of vessel patency is the underlying pathomechanism. The main scope of the Research Team "PULMONARY HYPERTENSION: PATHOPHYSIOLOGY AND NOVEL THERAPIES" relates to pulmonary hypertension pathophysiology and clinical management. Deciphering of the mechanisms of lung vascular remodeling and identification of novel molecular targets to alleviate and ultimately cure pulmonary hypertension is the main objective of this proposal. On the basis of a nationwide web-based Registry, a biobank, and highly competitive scientists, our group will study a number of molecular pathways causing pulmonary vascular remodeling in human and animal models of pulmonary hypertension, identify targets for therapy, foster drug development based on these targets and test novel treatments. Our main goal is to alleviate and cure pulmonary hypertension, a large burden to mankind, and to develop novel therapies.